Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
98.31 (1y: +7%)
Market Cap 18.45 B P/E(ttm) 32.50
Enterprise Value 18.1 B P/B 4.80
SHPG- NAS (USA)
Shire PLC
  • Currently 1/5
Business Predictability Rank: 1-Star (On Watch)
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$98.31
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash to Debt 1.347
SHPG's Cash to Debt is ranked higher than
64% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. SHPG: 1.347 )
SHPG' s 10-Year Cash to Debt Range
Min: 0.19   Max: No Debt
Current: 1.35
Equity to Asset 0.521
SHPG's Equity to Asset is ranked higher than
68% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. SHPG: 0.521 )
SHPG' s 10-Year Equity to Asset Range
Min: 0.28   Max: 0.83
Current: 0.52
0.28
0.83
Interest Coverage 27
SHPG's Interest Coverage is ranked higher than
75% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 27 )
SHPG' s 10-Year Interest Coverage Range
Min: 4   Max: No Debt
Current: 27
F-Score: 7
Z-Score: 4.27
M-Score: -2.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry		 vs
history
Operating margin (%) 20.30
SHPG's Operating margin (%) is ranked higher than
93% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. SHPG: 20.30 )
SHPG' s 10-Year Operating margin (%) Range
Min: -56.6   Max: 32.7
Current: 20.3
-56.6
32.7
Net-margin (%) 15.9
SHPG's Net-margin (%) is ranked higher than
91% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. SHPG: 15.9 )
SHPG' s 10-Year Net-margin (%) Range
Min: -59.6   Max: 24.2
Current: 15.9
-59.6
24.2
ROE (%) 19.6
SHPG's ROE (%) is ranked higher than
95% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 19.6 )
SHPG' s 10-Year ROE (%) Range
Min: -118.3   Max: 27.2
Current: 19.6
-118.3
27.2
ROA (%) 10.2
SHPG's ROA (%) is ranked higher than
94% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. SHPG: 10.2 )
SHPG' s 10-Year ROA (%) Range
Min: -33.5   Max: 13.6
Current: 10.2
-33.5
13.6
ROC (Joel Greenblatt) (%) 60.30
SHPG's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 60.30 )
SHPG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -437.5   Max: 567.7
Current: 60.3
-437.5
567.7
Revenue Growth (%) 9.5
SHPG's Revenue Growth (%) is ranked higher than
89% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 9.5 )
SHPG' s 10-Year Revenue Growth (%) Range
Min: 4.8   Max: 14.7
Current: 9.5
4.8
14.7
EBITDA Growth (%) 7.5
SHPG's EBITDA Growth (%) is ranked higher than
91% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 7.5 )
SHPG' s 10-Year EBITDA Growth (%) Range
Min: -2.4   Max: 37.3
Current: 7.5
-2.4
37.3
EPS Growth (%) 9.9
SHPG's EPS Growth (%) is ranked higher than
94% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 9.9 )
SHPG' s 10-Year EPS Growth (%) Range
Min: 0.2   Max: 62.2
Current: 9.9
0.2
62.2
» SHPG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

SHPG Guru Trades in Q2 2012

Ken Fisher 554,505 sh (New)
Steven Cohen 68,780 sh (+86.71%)
John Hussman 183,000 sh (unchged)
Pioneer Investments 128,500 sh (unchged)
Mario Gabelli 5,455 sh (-0.09%)
Jim Simons 270,515 sh (-4.35%)
» More
Q3 2012

SHPG Guru Trades in Q3 2012

John Paulson 1,370,800 sh (New)
Steven Cohen 117,843 sh (+71.33%)
Jim Simons 319,812 sh (+18.22%)
John Hussman Sold Out
Mario Gabelli 4,970 sh (-8.89%)
Pioneer Investments 88,500 sh (-31.13%)
Ken Fisher 2,480 sh (-99.55%)
» More
Q4 2012

SHPG Guru Trades in Q4 2012

Jim Simons 603,112 sh (+88.58%)
Pioneer Investments 88,500 sh (unchged)
John Paulson 1,370,800 sh (unchged)
Ken Fisher 2,424 sh (-2.26%)
Mario Gabelli 4,370 sh (-12.07%)
Steven Cohen 3,518 sh (-97.01%)
» More
Q1 2013

SHPG Guru Trades in Q1 2013

Steven Cohen 86,729 sh (+2365.29%)
Ken Fisher 2,715 sh (+12%)
Jim Simons 663,012 sh (+9.93%)
John Paulson 1,370,800 sh (unchged)
Pioneer Investments 88,500 sh (unchged)
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SHPG

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2013-03-31 Sold Out $89.83 - $101.63 $ 98.312%0
John Paulson 2012-09-30 New Buy0.99%$84.65 - $95.05 $ 98.319%1370800
John Hussman 2012-09-30 Sold Out 0.3%$84.65 - $95.05 $ 98.319%0
John Keeley 2012-03-31 Sold Out 0.0046%$97.29 - $108.2 $ 98.312%0
Mario Gabelli 2012-03-31 New Buy$97.29 - $108.2 $ 98.312%5460
John Keeley 2011-12-31 New Buy$88.04 - $103.9 $ 98.312%2105
John Keeley 2011-09-30 Sold Out 0.0035%$87.43 - $104 $ 98.312%0
John Keeley 2011-06-30 Reduce -36.62%$87.92 - $96.32 $ 98.317%2285
John Keeley 2011-03-31 New Buy$72.38 - $89.19 $ 98.3120%3605
George Soros 2010-09-30 Sold Out 0.01%$62.31 - $71.18 $ 98.3145%0
George Soros 2010-06-30 Reduce -49.52%$57.94 - $68.05 $ 98.3154%5300
Premium More recent guru trades are included for Premium Members only!!
» Financial Charts

Peter Lynch Chart

Top Ranked Articles about Shire PLC

John Paulson’s 4 Stocks Trading at 52-Week Lows
November 28, 2012
John Paulson - John Paulson’s 4 Stocks Trading At 52-Week Lows
John Paulson has gone from history-making returns in the subprime-mortgage market, to record losses in 2011, to being down 14% in his Advantage Plus Fund since the start of this year through September, according to Bloomberg. The investor, who has been bullish on gold for several years, has four stocks currently trading at 52-week low stock prices, three of which are gold miners, according to his GuruFolio available for download here. Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 32.50
SHPG's P/E(ttm) is ranked higher than
63% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 26.90 vs. SHPG: 32.50 )
SHPG' s 10-Year P/E(ttm) Range
Min: 9.77   Max: 262.58
Current: 32.5
9.77
262.58
P/B 4.80
SHPG's P/B is ranked higher than
62% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 3.56 vs. SHPG: 4.80 )
SHPG' s 10-Year P/B Range
Min: 1.57   Max: 10.95
Current: 4.8
1.57
10.95
P/S 4.10
SHPG's P/S is ranked higher than
80% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. SHPG: 4.10 )
SHPG' s 10-Year P/S Range
Min: 2.15   Max: 11.86
Current: 4.1
2.15
11.86
PFCF 17.20
SHPG's PFCF is ranked higher than
77% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 27.82 vs. SHPG: 17.20 )
SHPG' s 10-Year PFCF Range
Min: 8.06   Max: 669
Current: 17.2
8.06
669
EV-to-EBIT 22.7
SHPG's EV-to-EBIT is ranked higher than
66% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 22.58 vs. SHPG: 22.7 )
SHPG' s 10-Year EV-to-EBIT Range
Min: 3.9   Max: 543.2
Current: 22.7
3.9
543.2
PEG 1.8
SHPG's PEG is ranked higher than
68% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 1.80 vs. SHPG: 1.8 )
SHPG' s 10-Year PEG Range
Min: 0.55   Max: 1.8
Current: 1.8
0.55
1.8
Shiller P/E 90.1
SHPG's Shiller P/E is ranked lower than
100% of the Companies
in the Global Biotechnology industry.

( Industry Median: vs. SHPG: 90.1 )
SHPG' s 10-Year Shiller P/E Range
Min: 31.71   Max: 147.29
Current: 90.1
31.71
147.29

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 0.50
SHPG's Dividend Yield is ranked higher than
86% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 0.50 )
SHPG' s 10-Year Dividend Yield Range
Min: 0.18   Max: 0.66
Current: 0.5
0.18
0.66
Dividend Payout 0.1768
SHPG's Dividend Payout is ranked higher than
89% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. SHPG: 0.1768 )
SHPG' s 10-Year Dividend Payout Range
Min: 0.05   Max: 0.36
Current: 0.18
0.05
0.36
Dividend growth (3y) 6.8
SHPG's Dividend growth (3y) is ranked higher than
99% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 6.8 )
SHPG' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 42.4
Current: 6.8
0
42.4
Yield on cost (5-Year) 1.04
SHPG's Yield on cost (5-Year) is ranked higher than
90% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 1.04 )
SHPG' s 10-Year Yield on cost (5-Year) Range
Min: 0.37   Max: 1.37
Current: 1.04
0.37
1.37
Share Buyback Rate -2
SHPG's Share Buyback Rate is ranked higher than
64% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -0.60 vs. SHPG: -2 )
SHPG' s 10-Year Share Buyback Rate Range
Min: 1.1   Max: -20.9
Current: -2

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 19.6
SHPG's Price/Net Current Asset Value is ranked higher than
83% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: 45.80 vs. SHPG: 19.6 )
SHPG' s 10-Year Price/Net Current Asset Value Range
Min: 18.5   Max: 45.9
Current: 19.6
18.5
45.9
Price/Tangible Book 23.7
SHPG's Price/Tangible Book is ranked lower than
55% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 5.60 vs. SHPG: 23.7 )
SHPG' s 10-Year Price/Tangible Book Range
Min: 2.6   Max: 203.9
Current: 23.7
2.6
203.9
Price/DCF (Projected) 1.7
SHPG's Price/DCF (Projected) is ranked higher than
80% of the 127 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. SHPG: 1.7 )
SHPG' s 10-Year Price/DCF (Projected) Range
Min: 1   Max: 2.3
Current: 1.7
1
2.3
Price/Median PS Value 1
SHPG's Price/Median PS Value is ranked higher than
75% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. SHPG: 1 )
SHPG' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 2.1
Current: 1
0.7
2.1
Price/Peter Lynch Fair Value 1.7
SHPG's Price/Peter Lynch Fair Value is ranked lower than
51% of the 59 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. SHPG: 1.7 )
SHPG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.6   Max: 2.9
Current: 1.7
0.6
2.9
Price/Graham Number 5.4
SHPG's Price/Graham Number is ranked higher than
52% of the 212 Companies
in the Global Biotechnology industry.

( Industry Median: 2.70 vs. SHPG: 5.4 )
SHPG' s 10-Year Price/Graham Number Range
Min: 1   Max: 12
Current: 5.4
1
12
Earnings Yield (Greenblatt) 4.40
SHPG's Earnings Yield (Greenblatt) is ranked higher than
85% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 4.40 )
SHPG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 25.4
Current: 4.4
0.2
25.4
Forward Rate of Return (Yacktman) 21.96
SHPG's Forward Rate of Return (Yacktman) is ranked higher than
97% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 21.96 )
SHPG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.3   Max: 31.7
Current: 21.96
2.3
31.7

Business Description

Shire PLC is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. The principal activity of the company is the research and development, manufacture, sale and distribution of pharmaceutical products. It focuses its business on attention deficit hyperactivity disorder, human genetic therapies and gastrointestinal diseases as well as opportunities in other specialty therapeutic areas to the extent they arise through acquisitions. Its two segments are Specialty Pharmaceuticals and HGT. The group operates in Republic of Ireland, United Kingdom, North America, and Rest of World.
Company Website
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:SHP.UK, SHPGF.USA, S7E.Germany, SP2.Germany
» More Articles for NAS:SHPG

Headlines

Articles On GuruFocus.com
Paulson Says Bet Against Europe to Blame for Down Year, Slashed EU Holdings in Q3 Dec 06 2012 
John Paulson’s 4 Stocks Trading at 52-Week Lows Nov 28 2012 
Top 4 International Stocks at 52-Week Low Prices Oct 31 2012 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK